Immune to Cancer: The CRI Blog
-
Immunotherapy Shines at ASH and ESMO IO Conferences
Two conferences, one in America and one in Europe, highlight immunotherapy's continued progress and the important contributions…
-
Highlights of the 2nd Annual Rational Combinations 360° Conference
Biomarkers will be crucial to taking advantage of combination immunotherapy’s full potential
-
ASCO17 Recap: 7 Takeaways from the World’s Premier Clinical Cancer Conference
ASCO17’s presentations reveal that the field of immunotherapy is advancing along many fronts
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…
-
NY-ESO-1 Identified as a Promising Vaccine Target in Ovarian Cancer Patients
New study reveals effectiveness of immunotherapy vaccine against aggressive ovarian tumors.
-
Immunotherapy Shows Promise Against Previously Untreatable Stomach Cancer
Nivolumab improves survival in patients with advanced stomach cancer.
-
Checkpoint Inhibitors Benefit Lung Cancer Patients in Clinical Trials
Patients with metastatic non-small cell lung cancer could soon have a new first-line immunotherapy treatment option.
-
Phase 3 Trial Shows Nivolumab Improves Survival in Advanced Kidney Cancer
The trial ended early because data showed that patients lived longer on nivolumab compared to the standard-of-care…
-
New Clinical Trials to Offer Immunotherapy as Frontline Treatment for Lung Cancer
Patients with lung cancer will soon be able to receive immunotherapy as first-line treatment on an experimental…